G. D'Amato (Naples, Italy), J. Hurst (London, United Kingdom), K.F. Chung (London, United Kingdom)
Comparative in vitro performance of a new re-usable breath-actuated nebulizer (BAN) with other high performance systems intended for domiciliary use – 1: Table-top compressors
J. Malpass, M. Nagel, V. Avvakoumova, R. Ali, H. Schneider, J. Mitchell (London, Canada)
|   |
Formoterol and fluticasone reduce the deposition of pro-inflammatory collagens
M. Roth, J. Zhong, C.T. S‘ng, M. Tamm (Basel, Switzerland)
| |
Pharmaceutical development of a liquid formulation for pulmonary application of a peptide
H. Fischer, R. Lucas, H. Pietschmann, S. Tzotzos, B. Fischer (Vienna, Austria; Augusta, United States Of America)
| |
Tiotropium enhances the inhibitory effect of the long acting β2-agonist olodaterol on the release of IL-6 and IL8 by primary human lung fibroblasts of asthma patients
L. Costa, M. Roth, M. Tamm, P. Borger (Basel, Switzerland)
| |
Low dose inhaled LPS challenge – Reproducibility of the inflammatory response
O. Holz, F. Schaumann, O. Janssen, B. Lavae-Mokhtari, H. Biller, N. Krug, J.M. Hohlfeld (Hanover, Germany)
| |
Transactivation and transrepression in the repression of inflammatory gene expression by dexamethasone
E. King, J. Chivers, M. Giembycz, R. Newton (Calgary, Canada)
| |
Tiotropium provides sustained bronchodilation in asthmatics with persistent airflow obstruction uncontrolled despite treatment in accordance with guidelines
H. Kerstjens, P. Paggiaro, M. Vandewalker, E. Beck, M. Engel, R. Sigmund, W. Seibold, P. Moroni-Zentgraf, E. Bateman (Groningen, Netherlands; Pisa, Italy; Columbia, United States Of America; Rüdersdorf Brandenburg, Biberach an der Riss, Ingelheim am Rhein, Germany; Cape Town, South Africa)
| |
The effects of sildenafil on lung function in COPD
A. Goudie, P. Hopkinson, W. Anderson, B. Lipworth, A. Struthers (United Kingdom)
| |
Tolerability and efficacy of budesonide/formoterol via Turbuhaler® vs standard treatment in Japanese patients with moderate to severe COPD: 52-week phase III study results
M. Ichinose, H. Nakamura, N. Shijubo, T. Saito, H. Taniguchi, T. Tsuda, K. Yoshikawa, L.G. Carlsson (Wakayama, Kagawa, Hokkaido, Ibaraki, Aichi, Fukuoka, Japan; Molndal, Sweden)
| |
Effectiveness of tiotropium in low-risk patients according to new GOLD severity grading
D. Halpin, M. Decramer, B. Celli, A. Martín, I. Leimer, N. Metzdorf, D. Tashkin (Exeter, United Kingdom; Leuven, Belgium; Boston, New York, Los Angeles, United States Of America; Ingelheim, Germany)
| |
Efficacy and safety of fluticasone/formoterol compared to fluticasone alone in patients with asthma
T. Pertseva, S. Dissanayake, K. Kaiser (Dnipropetrovsk, Ukraine; Cambridge, United Kingdom; Muttenz, Switzerland)
| |
Does eosinophil cationic protein (ECP) predict asthma outcome and response to treatment in asthmatic patients?
E. Bacci, S. Cianchetti, M. Latorre, L. Melosini, A. Di Franco, F. Dente, P.L. Paggiaro (Pisa, Italy)
| |
Methacoline challenge test as an evaluator of response to statins in bronchial hyperresponsiveness
M. Malekmohammad, F. Fahimi, A. Fakharian, M. Habibi, P. Adimi (Tehran, Islamic Republic Of Iran)
| |
The GOLDEN-1 study: Safety and bronchodilatory effects of nebulized glycopyrrolate (EP-101) using high efficiency nebulizer in patients with COPD
C. Fogarty, E. Kerwin, K. Dunn, D. Singh, A. Tutuncu (Spartanburg, Medford, Raleigh, San Diego, United States Of America; Manchester, United Kingdom)
| |
Spacer cleaning: Nurse and patient survey examines current UK practice
M. Sanders, M. Levy, K. Thompson, R. Bruin (Harlow, Edinburgh, United Kingdom)
| |
Patterns of bronchodilator reversibility of FEV1 in asthma and COPD patients
T. Sahasrabudhe, M. Joshi, V. Oswal (Pimpri, Pune, India)
| |
Bronchodilator response and airway cytology as parameters for asthma control: A randomized clinical trial Protocol ID: APITA, NCT00597064, on August 1st, 2008
A.L. Fernandes, M.M. Amorim, L.B. Caetano, A. Araruna, I.L. Santoro (Sao Paulo, Brazil)
| |
The effect of smoking on severity of asthma and quality of life in patients treated with inhaled corticosteroids and long-acting b2-agonist (ICS/LABA)
G. Sergeeva, A. Emelyanov (Saint Petersburg, Russian Federation)
| |
The correction of monocyte-derived neohepatocytes from alpha1 antitrypsin deficient patients
G. McNab, R. Stockley (Birmingham, United Kingdom)
| |